

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Nadler, *et al.*
SERIAL NUMBER: 09/830,400 EXAMINER: Amy E. Juedes
FILING DATE: July 20, 2001 ART UNIT: 1644
FOR: CANCER IMMUNOTHERAPY AND DIAGNOSIS USING UNIVERSAL
TUMOR ASSOCIATED ANTIGENS, INCLUDING HTERT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER


Enclosed herewith for filing in the above-identified application please find the following documents:

1. Amendment and Response to October 16, 2008 Office Action (5 pgs.)
2. Petition for Extension of Time (1 pg.)
3. Check No. 26167 in the amount of \$555.00 for Extension fee;
4. Supplemental Information Disclosure Statement (2 pages);
5. Modified Form 1449/PTO (7 pages);
6. Copies of cited references: B6; C5-C137;
7. Check No. 26168 in the amount of \$180.00 for Information Disclosure Statement; and
8. Return Postcard.

Although Applicants believe no additional fees are due with this submission, the Commissioner is hereby authorized to charge any fee that may be due to Deposit Account No. 50-0311, Reference No. 20363-015 NATL.

If the enclosed papers are considered incomplete, the Mail Room is respectfully requested to contact the undersigned collect at (617) 542-6000, Boston, Massachusetts.

Respectfully submitted,



Ivor R. Elrifi, Reg. No. 39,529
Cynthia A. Kozakiewicz, Reg. No. 42,764
Attorney for Applicant
c/o MINTZ LEVIN
Tel: 617-542-6000
Fax: 617-542-2241
Customer No. 30623

Date: April 16, 2009



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Nadler et al.
SERIAL NUMBER: 09/830,400 EXAMINER : Amy E. Juedes
FILING DATE: July 20, 2001 ART UNIT : 1644
FOR: CANCER IMMUNOTHERAPY AND DIAGNOSIS USING UNIVERSAL
TUMOR ASSOCIATED ANTIGENS, INCLUDING HTERT

Mail Stop Amendment
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents.

This Supplemental Information Disclosure Statement is being filed after the mailing date of the first Office Action, but before the mailing date of either a final action under 37 C.F.R. §1.113 or a Notice of Allowance under 37 C.F.R. §1.311. The fee of \$180.00 as set forth in 37 C.F.R. §1.17(p) is enclosed. By the waiver of 37 CFR 1.98(a)(2)(ii) a copy of the U.S. Patent A4 is not submitted.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and sign the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Supplemental Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

04/17/2009 WAB/ELR1 00000027 09830400

180.00 OP


01 FC:1806

APPLICANT: Nadler et al.
U.S.S.N.: 09/830,400

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 20363-015 NATL.

Respectfully submitted,



Ivor R. Elrifi, Reg. No. 39,529
Cynthia A. Kozakiewicz, Reg. No. 42,764
Attorneys for Applicants
c/o MINTZ, LEVIN
Address all written correspondence to
Customer no.: 30623
Tel: (617) 542-6000
Fax: (617) 542-2241

4592808v.1